• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pembrolizumab for the Treatment of Hepatocellular Carcinoma.帕博利珠单抗用于治疗肝细胞癌。
Liver Cancer. 2019 May;8(3):143-154. doi: 10.1159/000500143. Epub 2019 Apr 29.
2
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
3
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.患者肝癌对纳武利尤单抗发生超敏反应后，使用帕博利珠单抗治疗。
Am J Health Syst Pharm. 2019 Oct 15;76(21):1749-1752. doi: 10.1093/ajhp/zxz189.
4
Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab.对帕博利珠单抗敏感的转移性肝细胞癌
Cureus. 2016 Jun 4;8(6):e631. doi: 10.7759/cureus.631.
5
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
6
Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.日本患者中微卫星高度不稳定型肝细胞癌的发病率及对帕博利珠单抗的反应
Hepatol Res. 2020 Jul;50(7):885-888. doi: 10.1111/hepr.13496. Epub 2020 Mar 6.
7
Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression.帕博利珠单抗治疗转移性肝细胞癌的独特临床和磁共振特征：假性进展后出现延迟反应的病例报告
Hepatol Commun. 2017 Dec 19;2(2):148-151. doi: 10.1002/hep4.1132. eCollection 2018 Feb.
8
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗在含铂化疗期间或之后出现疾病进展的复发性或转移性头颈部鳞状细胞癌。
Oncologist. 2017 Jul;22(7):873-878. doi: 10.1634/theoncologist.2016-0496. Epub 2017 May 22.
9
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.帕博利珠单抗对比甲氨蝶呤、多西他赛或西妥昔单抗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-040）：一项随机、开放标签、III 期研究。
Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.
10
Successful Treatment of Therapy-related Acute Promyelocytic Leukemia with All-trans-retinoic acid Following Epirubicin for Hepatocellular Carcinoma and Docetaxel and Pembrolizumab Therapies for Lung Carcinoma: A Triple Malignancy Case.在接受表柔比星治疗肝细胞癌、多西他赛和帕博利珠单抗治疗肺癌后，全反式维甲酸成功治疗与治疗相关的急性早幼粒细胞白血病：一例三联恶性肿瘤病例
Tokai J Exp Clin Med. 2020 Jul 20;45(2):92-96.

引用本文的文献

1
Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC.肿瘤微环境与肝癌经动脉及全身治疗耐药性之间的相互作用。
Cancer Drug Resist. 2025 Jul 2;8:33. doi: 10.20517/cdr.2024.212. eCollection 2025.
2
Wnt Pathway-Targeted Therapy in Gastrointestinal Cancers: Integrating Benchside Insights with Bedside Applications.胃肠道癌症中的Wnt信号通路靶向治疗：将实验室见解与临床应用相结合
Cells. 2025 Jan 24;14(3):178. doi: 10.3390/cells14030178.
3
Development of an LC-TOF/MS Method to Quantify Camrelizumab in Human Serum.建立一种 LC-TOF/MS 法测定人血清中卡瑞利珠单抗的浓度。
Molecules. 2024 Oct 14;29(20):4862. doi: 10.3390/molecules29204862.
4
Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress.肝细胞癌及其与微环境的多方面关系：攻克肝细胞癌的防御堡垒
Cancers (Basel). 2024 May 11;16(10):1837. doi: 10.3390/cancers16101837.
5
Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.肝细胞癌免疫治疗的治疗选择：现状与未来。
J Clin Transl Hepatol. 2024 Apr 28;12(4):389-405. doi: 10.14218/JCTH.2023.00462. Epub 2024 Feb 28.
6
A change point-based analysis procedure for improving the success rate of decision-making in clinical trials with delayed treatment effects.一种基于变化点的分析程序，用于提高具有延迟治疗效果的临床试验中决策的成功率。
Front Pharmacol. 2023 Sep 11;14:1186456. doi: 10.3389/fphar.2023.1186456. eCollection 2023.
7
A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.针对晚期肝细胞癌的免疫疗法多学科治疗方法。
J Liver Cancer. 2023 Sep;23(2):316-329. doi: 10.17998/jlc.2023.09.04. Epub 2023 Sep 22.
8
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice.肝细胞癌全身药物治疗的潜在预测生物标志物：在临床实践中的预期用途
Cancers (Basel). 2023 Aug 30;15(17):4345. doi: 10.3390/cancers15174345.
9
Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.乐伐替尼联合抗程序性死亡蛋白1（PD-1）治疗是初始不可切除肝细胞癌患者可行的转化性切除策略：一项回顾性研究。
Front Oncol. 2022 Nov 24;12:1046584. doi: 10.3389/fonc.2022.1046584. eCollection 2022.
10
At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy.在心脏病学与肿瘤学的交叉领域：转化生长因子β作为三阴性乳腺癌治疗的临床可转化疗法以及化疗后心肌病的主要调节因子。
Cancers (Basel). 2022 Mar 19;14(6):1577. doi: 10.3390/cancers14061577.

本文引用的文献

1
Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence.肝细胞癌及周围组织中的免疫基因表达谱可预测肿瘤复发时间。
Liver Cancer. 2018 Sep;7(3):277-294. doi: 10.1159/000486764. Epub 2018 Mar 6.
2
Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma.仑伐替尼的极高客观缓解率：其临床意义及改变肝细胞癌的治疗模式
Liver Cancer. 2018 Sep;7(3):215-224. doi: 10.1159/000492533. Epub 2018 Aug 24.
3
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
4
Combination Cancer Immunotherapy in Hepatocellular Carcinoma.肝细胞癌的联合癌症免疫疗法
Liver Cancer. 2018 Mar;7(1):20-27. doi: 10.1159/000486487. Epub 2018 Jan 31.
5
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
6
Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.晚期肝细胞癌全身治疗的疗效与安全性：一项III期试验的网状Meta分析
Liver Cancer. 2017 Nov;6(4):337-348. doi: 10.1159/000481314. Epub 2017 Oct 19.
7
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
8
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.肝细胞癌的分子靶向药物：现状与未来展望
Liver Cancer. 2017 Feb;6(2):101-112. doi: 10.1159/000452138. Epub 2016 Dec 15.
9
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.肝细胞癌中的免疫检查点阻断：2017年更新
Liver Cancer. 2016 Nov;6(1):1-12. doi: 10.1159/000449342. Epub 2016 Nov 29.
10
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.错配修复缺陷肿瘤中的程序性死亡受体-1阻断
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

出版信息

Liver Cancer. 2019 May;8(3):143-154. doi: 10.1159/000500143. Epub 2019 Apr 29.

DOI:10.1159/000500143
PMID:31192152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6547263/
Abstract
摘要